Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Work In Process: 2021-2025

Historic Work In Process for Aytu Biopharma (AYTU) over the last 5 years, with Sep 2025 value amounting to $862,000.

  • Aytu Biopharma's Work In Process fell 74.37% to $862,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $862,000, marking a year-over-year decrease of 74.37%. This contributed to the annual value of $1.4 million for FY2025, which is 75.88% down from last year.
  • Latest data reveals that Aytu Biopharma reported Work In Process of $862,000 as of Q3 2025, which was down 37.58% from $1.4 million recorded in Q2 2025.
  • Aytu Biopharma's Work In Process' 5-year high stood at $5.7 million during Q2 2024, with a 5-year trough of $862,000 in Q3 2025.
  • Its 3-year average for Work In Process is $3.0 million, with a median of $3.0 million in 2023.
  • In the last 5 years, Aytu Biopharma's Work In Process soared by 93.67% in 2024 and then plummeted by 75.88% in 2025.
  • Aytu Biopharma's Work In Process (Quarterly) stood at $2.2 million in 2021, then grew by 28.99% to $2.8 million in 2022, then decreased by 4.60% to $2.7 million in 2023, then grew by 16.04% to $3.1 million in 2024, then tumbled by 74.37% to $862,000 in 2025.
  • Its last three reported values are $862,000 in Q3 2025, $1.4 million for Q2 2025, and $2.1 million during Q1 2025.